ReviewInfection2026
Targeting antimicrobial resistance through vaccinology: a review of preclinical and clinical pipeline vaccines against WHO priority bacterial pathogens.
Review in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecular Diagnostics for WHO Priority Bacterial Pathogens: A Bibliometric Mapping of Diagnostic Platforms, Resistance Markers, and Antimicrobial Resistance Research Trends.MicrobiologyOpen · 2026Review
- Point-of-Care Diagnostic Technologies for Antimicrobial Resistance: Principles, Platforms, Clinical Impact, and Future Directions.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesAntimicrobial resistance (AMR) represents a critical and escalating global health threat, with resistant bacterial infections contributing to millions of deaths annually. While the development of novel antibiotics remains essential, preventive strategies, particularly vaccination, offer a sustainable and underutilized approach to mitigating AMR. This review aims to provide a comprehensive overview of vaccine development efforts targeting bacterial pathogens listed in the World Health Organization (WHO) 2024 Priority Pathogens report.
methodsWe systematically analyzed both preclinical and clinical-stage vaccine candidates, focusing on platform technologies, antigen selection strategies, and pathogen-specific challenges.
resultsAdvances in mRNA platforms, outer membrane vesicles, reverse vaccinology, and structure-guided antigen design are accelerating vaccine development. However, significant challenges persist, including antigenic diversity, limited correlates of protection, and regulatory complexity.
conclusionVaccination represents a promising strategy to reduce antibiotic use and limit resistance prevalence. By integrating current pipeline data with AMR reduction frameworks, this review provides an updated resource to guide vaccine design, investment prioritization, and global AMR control strategies.
Indexed as
Identifiers
41722003What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.